Along with the KRAS inhibitor sotorasib (Skoulidis et al., 2021), the proof-of-concept of tunlametininb as a therapeutic approach towards NRAS mutant melanoma may broaden the once challenging area of RAS mutant cancer. Here, KRAS is linked to melanoma.